ABSTRACT
Over the last decade, the isoxazoline motif has become the intense focus of crop protection and animal health companies in their search for novel pesticides and ectoparasiticides. Herein we report the discovery of sarolaner, a proprietary, optimized-for-animal health use isoxazoline, for once-a-month oral treatment of flea and tick infestation on dogs.
Subject(s)
Antiparasitic Agents/chemistry , Antiparasitic Agents/therapeutic use , Dog Diseases/drug therapy , Flea Infestations/veterinary , Isoxazoles/chemistry , Isoxazoles/therapeutic use , Tick Infestations/veterinary , Animals , Antiparasitic Agents/pharmacology , Ctenocephalides/drug effects , Dogs , Female , Flea Infestations/drug therapy , Isoxazoles/pharmacology , Male , Rhipicephalus sanguineus/drug effects , Siphonaptera/drug effects , Tick Infestations/drug therapy , Ticks/drug effectsABSTRACT
Haematobia irritans (horn fly) infestation in cattle is responsible for over a billion dollars a year in global economic loss due to decreased milk production and lower feed conversion. There is significant need for new insecticidal agents since current treatments such as organophosphates and pyrethroids suffer from field resistance. Isoxazoline oxime ethers represent a new class of γ-aminobutyric acid (GABA) receptor channel blockers which show good activity (LD(90) = 1.0 µg/mL) against horn flies in an in vitro feed assay and have demonstrated efficacy (>90% reduction at 1.0mg/kg) as a topical treatment in a field study.
